© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 1, 34-41,
January 5, 2000
© 2000 Oxford University Press
Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides
Affiliations of authors: H. Miayake, The Prostate Centre, Vancouver General Hospital, BC, Canada; A. Tolcher, Department of Medical Oncology, British Columbia Cancer Agency, Canada; M. E. Gleave, The Prostate Centre, Vancouver General Hospital, and Division of Urology, University of British Columbia, Canada.
Correspondence to: Martin E. Gleave, M.D., Division of Urology, University of British Columbia, D-9, 2733 Heather St., Vancouver, BC V5Z 3J5, Canada (e-mail: gleave{at}unixg.ubc.ca).
BACKGROUND: Increased expression of the bcl-2 gene has been observed in prostate cancer cells after androgen withdrawal and has been associated with the development of androgen independence and chemoresistance. The objective of this study was to determine whether antisense Bcl-2 oligodeoxynucleotides could enhance paclitaxel cytotoxicity and delay androgen-independent progression. METHODS: Northern and western blot analyses were used to measure changes in Bcl-2 expression in mouse Shionogi tumor cells after treatment with antisense Bcl-2 oligodeoxynucleotides and/or paclitaxel. Growth inhibition and induction of apoptotic cell death were assessed with the use of standard methods. All P values are two-sided. RESULTS: Treatment of Shionogi tumor cells with 500 nM antisense Bcl-2 oligodeoxynucleotides decreased expression of Bcl-2 messenger RNA (mRNA) by approximately 85%. Paclitaxel treatment induced Bcl-2 protein phosphorylation but did not alter Bcl-2 mRNA expression. Antisense Bcl-2 oligodeoxynucleotide treatment substantially enhanced paclitaxel chemosensitivity in a dose-dependent manner. Characteristic apoptotic DNA laddering and cleavage of poly(adenosine diphosphate-ribose) polymerase were demonstrated only after combined treatment. Adjuvant in vivo administration of antisense Bcl-2 oligodeoxynucleotides and micellar paclitaxel following castration resulted in a statistically significant delay of androgen-independent, recurrent tumors compared with administration of either agent alone (P<.001, Mantel-Cox log-rank test). Combination therapy also statistically significantly inhibited the growth of established hormone-refractory tumors compared with treatment with either agent alone (P<.001, Student's t test). CONCLUSIONS. Combined treatment with antisense Bcl-2 oligodeoxynucleotides and paclitaxel could be a novel and attractive strategy to inhibit progression to androgen-independent disease as well as growth of hormone-refractory prostate cancer through deprivation of Bcl-2 function.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Rom, G. von Minckwitz, W. Eiermann, M. Sievert, B. Schlehe, F. Marme, F. Schuetz, A. Scharf, M. Eichbaum, H.-P. Sinn, et al. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study Ann. Onc., May 13, 2008; (2008) mdn280v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mita, L. Ochoa, E. K. Rowinsky, J. Kuhn, G. Schwartz, L. A. Hammond, A. Patnaik, I.-T. Yeh, E. Izbicka, K. Berg, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (GenasenseTM, G3139) and irinotecan in patients with metastatic colorectal cancer Ann. Onc., February 1, 2006; 17(2): 313 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. So, S. Sinnemann, D. Huntsman, L. Fazli, and M. Gleave Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo Mol. Cancer Ther., December 1, 2005; 4(12): 1837 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, P. Rocchi, H. Miyake, L. Fazli, B. Vessella, U. Zangemeister-Wittke, and M. E. Gleave A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells Mol. Cancer Ther., November 1, 2005; 4(11): 1689 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J.C. Eigl, S. E. Eggener, J. Baybik, S. Ettinger, K. N. Chi, C. Nelson, Z. Wang, and M. E. Gleave Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4905 - 4911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Tolcher, K. Chi, J. Kuhn, M. Gleave, A. Patnaik, C. Takimoto, G. Schwartz, I. Thompson, K. Berg, S. D'Aloisio, et al. A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3854 - 3861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Ghobrial, T. E. Witzig, and A. A. Adjei Targeting Apoptosis Pathways in Cancer Therapy CA Cancer J Clin, May 1, 2005; 55(3): 178 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bianco, R. Caputo, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A. R. Bianco, F. Ciardiello, and G. Tortora Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4858 - 4864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Benimetskaya, T. Wittenberger, C. A. Stein, H.-P. Hofmann, C. Weller, J. C. Lai, P. Miller, and V. Gekeler Changes in Gene Expression Induced by Phosphorothioate Oligodeoxynucleotides (Including G3139) in PC3 Prostate Carcinoma Cells Are Recapitulated at Least in Part by Treatment with Interferon-{beta} and -{gamma} Clin. Cancer Res., June 1, 2004; 10(11): 3678 - 3688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lai, L. Benimetskaya, R. M. Santella, Q. Wang, P. S. Miller, and C. A. Stein G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner Mol. Cancer Ther., October 1, 2003; 2(10): 1031 - 1043. [Abstract] [Full Text]
|
|
|
|
|
|
T. Tauchi, M. Sumi, A. Nakajima, G. Sashida, T. Shimamoto, and K. Ohyashiki BCL-2 Antisense Oligonucleotide Genasense Is Active against Imatinib-resistant BCR-ABL-positive Cells Clin. Cancer Res., September 15, 2003; 9(11): 4267 - 4273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu and Y. Gazitt Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells Blood, May 15, 2003; 101(10): 4105 - 4114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Loomis, R. Carbone, M. Reiss, and J. Lacy Bcl-2 Antisense (G3139, Genasense) Enhances the in Vitro and in Vivo Response of Epstein-Barr Virus-associated Lymphoproliferative Disease to Rituximab Clin. Cancer Res., May 1, 2003; 9(5): 1931 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zellweger, K. Chi, H. Miyake, H. Adomat, S. Kiyama, K. Skov, and M. E. Gleave Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin Clin. Cancer Res., October 1, 2002; 8(10): 3276 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello and G. Tortora Inhibition of bcl-2 as cancer therapy Ann. Onc., April 1, 2002; 13(4): 501 - 502. [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al. The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tortora and F. Ciardiello Protein Kinase A Type I: A Target For Cancer Therapy Clin. Cancer Res., February 1, 2002; 8(2): 303 - 304. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Benimetskaya, P. Miller, S. Benimetsky, A. Maciaszek, P. Guga, S. L. Beaucage, A. Wilk, A. Grajkowski, A. L. Halperin, and C. A. Stein Inhibition of Potentially Anti-Apoptotic Proteins by Antisense Protein Kinase C-alpha (Isis 3521) and Antisense bcl-2 (G3139) Phosphorothioate Oligodeoxynucleotides: Relationship to the Decreased Viability of T24 Bladder and PC3 Prostate Cancer Cells Mol. Pharmacol., December 1, 2001; 60(6): 1296 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, I. Hara, S. Kamidono, and M. E. Gleave Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model Clin. Cancer Res., December 1, 2001; 7(12): 4245 - 4252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Kanwar, W.-P. Shen, R. K. Kanwar, R. W. Berg, and G. W. Krissansen Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy J Natl Cancer Inst, October 17, 2001; 93(20): 1541 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zellweger, H. Miyake, S. Cooper, K. Chi, B. S. Conklin, B. P. Monia, and M. E. Gleave Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 934 - 940. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Berg, M. Werner, P. J. Ferguson, C. Postenka, M. Vincent, D. J. Koropatnick, and E. Behrend Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tortora, R. Caputo, V. Damiano, R. Bianco, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and F. Ciardiello Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis Clin. Cancer Res., August 1, 2001; 7(8): 2537 - 2544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Tolcher Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel Oncologist, June 1, 2001; 6(2008): 40 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fujimoto-Ouchi, Y. Tanaka, and T. Tominaga Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5'-Deoxy-5-fluorouridine and Docetaxel in Breast Cancer Models Clin. Cancer Res., April 1, 2001; 7(4): 1079 - 1086. [Abstract] [Full Text]
|
|
|
|
|
|
A. Fernandez, T. Udagawa, C. Schwesinger, W.-D. Beecken, E. Achilles-Gerte, T. J. McDonnell, and R. J. D'Amato Angiogenic Potential of Prostate Carcinoma Cells Overexpressing bcl-2 J Natl Cancer Inst, February 7, 2001; 93(3): 208 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Bruce, A. Giacca, and A. Medline Possible Mechanisms Relating Diet and Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1271 - 1279. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Acquisition of Chemoresistant Phenotype by Overexpression of the Antiapoptotic Gene Testosterone-repressed Prostate Message-2 in Prostate Cancer Xenograft Models Cancer Res., May 1, 2000; 60(9): 2547 - 2554. [Abstract] [Full Text]
|
|
|
|
|
|
H. Miyake, K. N. Chi, and M. E. Gleave Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo Clin. Cancer Res., May 1, 2000; 6(5): 1655 - 1663. [Abstract] [Full Text]
|
|
|
|
|
|
M. Srivastava, N. Ahmad, S. Gupta, and H. Mukhtar Involvement of Bcl-2 and Bax in Photodynamic Therapy-mediated Apoptosis. ANTISENSE Bcl-2 OLIGONUCLEOTIDE SENSITIZES RIF 1 CELLS TO PHOTODYNAMIC THERAPY APOPTOSIS J. Biol. Chem., April 27, 2001; 276(18): 15481 - 15488. [Abstract] [Full Text] [PDF]
|
|